Danish drugmaker Novo Nordisk said several hundred counterfeit units of its diabetes drug Ozempic were being distributed in ...

Beyond diabetes and obesity, Novo Nordisk is diversifying its portfolio by developing Mim8 for hemophilia A, with plans to submit it for regulatory approval soon. Alhemo (concizumab) recently ...

Novo Nordisk got the go-ahead for its once-daily prophylactic haemophilia therapy Alhemo (concizumab) at its second attempt, having been turned down by the US regulator last year. The tissue ...

Novo Nordisk's anti-TFPI antibody concizumab has ... Concizumab – which has the trade name Alhemo – is already approved in other markets, including Japan, Australia, and Switzerland, but ...

Novo Nordisk has beaten Wall Street's revenue estimates ... while its competitor has only one [Alhemo]. Eli Lilly's R&D portfolio includes 77 projects, 22 of which are in Phase 3.

Alhemo (concizumab-mtci) is approved to prevent or reduce bleeding problems in people with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors. It is given once a ...

Qfitlia’s monthly regimen already gives it an advantage over Novo Nordisk’s daily Alhemo (concizumab) and Pfizer’s weekly Hympavzi (marstacimab), two of the most recent drugs approved by the FDA for ...

The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...